The B.1.617 variant can be being referred to as a ‘double mutant’ or the ‘Indian pressure’.
“Initial positive neutralisation studies of B.1.617, with both post-Covaxin or Covishield sera, are correlatable with milder disease during post-vaccination breakthrough infections. This is a positive while we get quantitative data for better understanding of infection protection,” Agrawal tweeted.
IGIB is an institute beneath the Council for Scientific and Industrial Research (CSIR).
Another study by the Centre for Cellular and Molecular Biology (CCMB) in Hyderabad beneath the CSIR suggests that early outcomes utilizing in-vitro neutralisation assay present that each convalescent (prior an infection) sera and Covishield-vaccinated sera provide safety against the B.1.617 variant.
“Very preliminary but encouraging result: #Covishield protects against #B1617. Early results using in vitro neutralization assay show that both convalescent (prior infection) sera and Covishield vaccinated sera offer protection against the B.1.617 variant, aka #DoubleMutant,” CCMB Director Rakesh Mishra tweeted final week.
The B.1.617 variant has three new spike protein mutations. Two mutations — E484Q and L452R — are within the space essential for antibody-based neutralisation.
The third mutation — P681R — permits the virus to enter cells somewhat higher. These are defining traits of the variant.
The B.1.617 variant of SARS-CoV2 has been discovered prevalent largely in Maharashtra and Delhi which were severely hit by a devastating second wave of the pandemic.
#Covishield #Covaxin #effective #Indian #pressure #coronavirus #study #suggests